Zacks Investment Research downgraded Baxter International Inc (NYSE:BAX) to Hold in a report released today.
- Updated: October 17, 2016
Zacks Investment Research has downgraded Baxter International Inc (NYSE:BAX) to Hold in a report released on 10/17/2016.
Previously on 10/13/2016, Zacks Investment Research reported about Baxter International Inc (NYSE:BAX) raised the target price from $0.00 to $53.00. At the time, this indicated a possible upside of 0.13%.
Yesterday Baxter International Inc (NYSE:BAX) traded -0.03% lower at $47.45. The company’s 50-day moving average is $47.05 and its 200-day moving average is $45.57. The last stock close price is up 4.09% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,111,090 shares of the stock were exchanged, down from an average trading volume of 3,796,810
See Chart Below
Baxter International Inc has a 52 week low of $33.78 and a 52 week high of $49.49 with a P/E ratio of 5.45 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 11 firms have issued a report on the stock. The consensus target price is $48.82 with 0 firms rating the stock a strong buy, 3 firms rating the stock a buy, 11 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.
General Information About Baxter International Inc (NYSE:BAX)
Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.